Impact of surgical resection rate on survival in gastric cancer: nationwide study

C.-H. Kung 1, 2, *, C. Jestin Hannan 3, G. Linder 4, J. Johansson 4, M. Nilsson 1, 5, J. Hedberg 3 and M. Lindblad 1, 5

1Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
2Department of Surgery, Skellefteå County Hospital, Skellefteå, Sweden
3Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
4Department of Surgery, Lund University, Lund, Sweden
5Department of Digestive Surgery, Karolinska University Hospital, Stockholm, Sweden

*Correspondence to: Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Karolinska University Hospital, C1:77 Huddinge, 141 86 Stockholm, Sweden (e-mail: chih-han.kung@ki.se)

Abstract

Background: There are marked geographical variations in the proportion of patients undergoing resection for gastric cancer. This study investigated the impact of resection rate on survival.

Methods: All patients with potentially curable gastric cancer between 2006 and 2017 were identified from the Swedish National Register of Oesophageal and Gastric Cancer. The annual resection rate was calculated for each county per year. Resection rates in all counties for all years were grouped into tertiles and classified as low, intermediate or high. Survival was analysed using the Cox proportional hazards model.

Results: A total of 3465 patients were diagnosed with potentially curable gastric cancer, and 1934 (55.8 per cent) were resected. Resection rates in the low (1261 patients), intermediate (1141) and high (1063) tertiles were 0–50.0, 50.1–62.5 and 62.6–100 per cent respectively. The multivariable Cox analysis revealed better survival for patients diagnosed in counties during years with an intermediate versus low resection rate (hazard ratio (HR) 0.81, 95 per cent c.i. 0.74 to 0.90; P < 0.001) and high versus low resection rate (HR 0.80, 0.73 to 0.88; P < 0.001).

Conclusion: This national register study showed large regional variation in resection rates for gastric cancer. A higher resection rate appeared to be beneficial with regard to overall survival for the entire population.

Introduction

Gastric cancer is the fifth most common malignancy worldwide and accounts for the third highest cancer-related mortality rate. Modern treatment of gastric cancer has evolved with the development of specialist multidisciplinary teams and wider use of surgical resection in conjunction with other therapies as standard of care. Perioperative chemotherapy is most commonly used in Europe, adjuvant chemotherapy in North America, and adjuvant chemotherapy in eastern Asia.

Despite recent advances, surgical resection of the primary tumour and regional lymph node stations remains the principal treatment for potentially curable disease. Better diagnostics and greater staging accuracy, as well as improved understanding of patient co-morbidities and functional status, have all contributed to improvements in outcome. There is, however, large variation in the proportion of patients undergoing curative resection between and within countries. Historically, in a review of non-Japanese studies up to 1990, the average surgical exploration rate of all studies, involving 80738 patients, was 74.1 per cent, but the resection rate was only 35.2 per cent, and the rate of resections deemed radical was 17.8 per cent. A more recent study from the Netherlands also found marked variation in resection rates depending on where, and during what time period, treatment was undertaken. Surgery for gastric cancer designed to cure was performed historically in almost all hospitals with surgical capacity in Sweden. Over the past 20 years, resectional surgery for gastric cancer has gradually been centralized to specialized units, whereas diagnostics, preoperative investigation, some limited palliative procedures, and some oncological therapies are still usually performed at the hospital of diagnosis.

The aim of the present study was to identify any differences in resection rates by county and see whether this was related to survival. An optimized curative resection rate should be of value for the entire population of patients with potentially curable gastric cancer.

Methods

This was a national register-based cohort study based on the National Register of Oesophageal and Gastric Cancer (NREV). The register has detailed data on all patients with gastric cancer in Sweden, including baseline characteristics, operative details, and postoperative complications. The register has previously been validated and holds data of excellent quality with high
completeness\textsuperscript{14}. Data from NREV were cross-matched with the Swedish Patient Register, Prescribed Drug Register, Cause of Death Register, Total Population Register and Education Register to obtain additional patient exposure and outcome information, as described previously\textsuperscript{15,16}. The study was approved by the regional ethics committee (EPN Stockholm Dnr 2016/1486-32 and 2013/596-31/3).

Study population
All patients in Sweden diagnosed with gastric cancer and gastroesophageal junction cancer, Siewert type III, in 2006–2017 were considered for inclusion. Only patients with registry data indicating potentially curable disease were included, thereby excluding patients registered with clinical metastatic disease (cM1) or unknown metastatic status (cMx).

Regions and regional multidisciplinary team conference
The healthcare system of Sweden is organized in 21 counties that have independent responsibility for the provision of healthcare to their population. Most counties have several hospitals, providing general healthcare. Neighbouring counties are organized into larger regions that offer highly specialized care, resulting in six regions that each have one tertiary referral centre, each covering a population from around 900 000 to roughly over 2 million. The two last decades of gradual centralization of gastric resectional surgery have resulted in regional referral to the tertiary centre for each region, but referral to other regions is possible in selected cases. Individual patient treatment recommendations are typically made in each of the six regional multidisciplinary team (MDT) conferences, held at least weekly by video conference, connecting hospitals in the counties of each region. Referral to the regional MDT conference is at the discretion of each diagnosing hospital.

Exposure
For every patient, the county of residence at the time of diagnosis was registered. Each county had its resection rate for gastric cancer calculated for each year during the study period by dividing the number of patients undergoing resection for gastric cancer with the total number of patients diagnosed in that county. All patients, irrespective of resection or not, were assigned a resection rate exposure, corresponding to the resection rate of their county of residence for the particular year in which they were diagnosed. The resection rate of all patients was grouped into tertiles (low, intermediate and high).

Outcome
The primary outcome was overall survival from time of diagnosis to death from any cause, emigration, or censorship date of 11 March 2018, whichever came first.

Statistical analysis
Data are presented as mean(s.d.) values and actual counts with percentages. Continuous variables were analysed with ANOVA, and categorical variables with the $\chi^2$ test. Survival was presented using the Kaplan–Meier method with the log rank test, and multivariable assessment of survival was performed with the Cox proportional hazards model. The multivariable model included only variables with information on both resected and non-resected patients, thereby excluding perioperative chemotherapy. The model included resection rate (categorized into low, intermediate and high tertiles), age (per year increment), sex (male or female), ASA grade (categorized as I–II, III–IV and missing), clinical tumour stage according to TNM 8 (categorized as I, II, III, IVa and missing), Charlson Co-morbidity Index (CCI) (categorized as a score of 0–1, 2, and 3 or more), educational level (categorized as 9 years or less, 10–12 years, more than 12 years, and missing) and decision-making in the MDT conference (yes or no). The variables were chosen based on clinical importance, and the model was decided upon \textit{a priori}. Sensitivity analyses were done for survival when resection rates were calculated: by use of 2-, 4- and 6-year periods instead of annually; in an extended study population including all patients with cM disease; and in a modified population that excluded non-resected patients who died within the median time frame from diagnosis to surgery of resected patients, to adjust for immortal time bias. Missing data were handled by the missing-indicator method. All statistical analyses were performed with IBM SPSS\textsuperscript{\textregistered} Statistics version 26 (IBM, Armonk, NY, USA).

Results
A total of 3465 patients diagnosed with clinically non-metastatic gastric adenocarcinoma were included in the analysis. Patient selection is shown in Fig. 1. Of these patients, 1934 (55.8 per cent) had a resection. The annual county-specific resection rate varied from 0 to 100 (5th to 95th percentile 25.0–85.7) per cent. The resection rate was 0–50.0 per cent in the low tertile (1261 patients), 50.1–62.5 per cent in the intermediate tertile (1141 patients), and 62.6–100 per cent in the high tertile (1063 patients). Baseline characteristics of the patients are shown in Table 1. In general, patients in intermediate and high resection rate tertiles had a lower ASA grade, less advanced tumour stage, and less co-morbidity than those in the low resection rate tertile.

Among the 1934 resected patients, 621 patients (32.1 per cent) received preoperative chemotherapy: 164 (33.6 per cent) of 488 patients in the low resection rate tertile, 259 (39.3 per cent) of 659 in the intermediate tertile, and 198 (25.2 per cent) of 787 in the high tertile.

The mean resection rate for each county during the entire study period showed a large variation, ranging from approximately 43.0 to 71.4 per cent. The annual resection rate within each county also varied during the study period, so that all counties, depending on year of analysis, had patients in all resection rate tertiles (Fig. 2).

![Fig. 1 Flow diagram of patient selection for the study](image-url)
Survival

Overall median survival for the whole cohort was 18.4 months, with median overall survival of 14.2, 20.9 and 21.9 months for the low, intermediate and high resection rate tertiles respectively. Corresponding 5-year survival rates were 19.0, 26.9 and 27.8 per cent respectively ($P < 0.001$) ($\text{Fig. 3}$).

Multivariable assessment revealed improved survival for individuals diagnosed in a county during a year with an intermediate or high resection rate versus a low resection rate: hazard ratio (HR) 0.81, 95 per cent c.i. 0.74 to 0.90 ($P < 0.001$) and HR 0.80, 0.73 to 0.88 ($P < 0.001$) respectively. Age, ASA grade, tumour stage and decision taken in an MDT setting were also independently associated with survival, whereas sex, educational level and co-morbidity had no such impact ($\text{Table 2}$).

Sensitivity analysis

Sensitivity analyses showed that when 2-, 4- and 6-year periods were used for the resection rate instead of annual periods for the individual counties, similar results were obtained to those in the main analysis ($\text{Table 3}$). When adjusting for immortal time bias, the results also showed no differences from the main analysis.

Discussion

This national register study revealed large variation between different counties in resection rates among patients with non-metastatic gastric adenocarcinoma. Intermediate and high resection rates were associated with survival benefit for the entire population compared with low resection rates. The factors associated with improved survival were lower age, lower ASA grade, lower clinical tumour stage and treatment decision taken after an MDT conference.

As resection of the tumour is the main element in therapy aimed at cure for gastric adenocarcinoma, it is not surprising that a high resection rate would correlate with improved survival. This has been reported previously in a Dutch population-based study.$^{13}$ Resection rates for gastric cancer vary between Western European countries, ranging from 21.6 to 41.9 per cent in all

| Resection rate | Low (0–50.0%) (n = 1261) | Intermediate (50.1–62.5%) (n = 1141) | High (62.6–100%) (n = 1063) | All patients (n = 3465) | $P^\dagger$ |
|----------------|---------------------------|--------------------------------------|-----------------------------|------------------------|---------|
| Age (years)$^*$ | 73(12)                    | 72(12)                               | 72(12)                      | 72(12)                 | 0.064$^\ddagger$ |
| Sex            | M 747 (59.2)              | 652 (57.1)                           | 613 (57.7)                  | 2012 (58.1)            | 0.554$^\ddagger$ |
| F 514 (40.8)   | 489 (42.9)                | 450 (42.3)                           | 1453 (41.9)                |                        |         |
| ASA grade      | I–II 729 (57.8)           | 741 (65.0)                           | 676 (63.6)                  | 2146 (61.9)            | $< 0.001$ |
| III–IV         | 382 (30.3)                | 371 (32.5)                           | 322 (30.3)                  | 1075 (31.0)            | $< 0.001$ |
| Missing        | 150 (11.9)                | 29 (2.5)                             | 65 (6.1)                    | 244 (7.0)              |         |
| Clinical tumour stage |                 |                                       |                             |                        |         |
| I              | 237 (18.8)                | 289 (25.3)                           | 304 (28.6)                  | 830 (24.0)             |         |
| II             | 356 (28.2)                | 329 (28.8)                           | 283 (26.6)                  | 968 (27.9)             |         |
| III            | 242 (19.2)                | 234 (20.5)                           | 182 (17.1)                  | 658 (19.0)             |         |
| IVa            | 18 (1.4)                  | 7 (0.6)                              | 3 (0.3)                     | 28 (0.8)               |         |
| Missing        | 408 (32.4)                | 282 (24.7)                           | 291 (27.4)                  | 981 (28.3)             |         |
| CCI score      | 0–1 424 (33.6)            | 362 (31.7)                           | 385 (36.2)                  | 1171 (33.8)            | 0.003   |
|                | 2 177 (14.0)              | 202 (17.7)                           | 192 (18.1)                  | 571 (16.5)             |         |
|                | $\geq3$ 660 (52.3)        | 577 (50.6)                           | 486 (45.7)                  | 1723 (49.7)            |         |
| Educational level (years) |       |                                       |                             |                        | $< 0.001$ |
| $\leq9$ years  | 519 (41.2)                | 430 (37.7)                           | 414 (38.9)                  | 1363 (39.3)            |         |
| $10–12$        | 465 (36.9)                | 431 (37.8)                           | 341 (32.1)                  | 1237 (35.7)            |         |
| $>12$          | 188 (14.9)                | 186 (16.3)                           | 139 (13.1)                  | 513 (14.8)             |         |
| Missing        | 89 (7.1)                  | 94 (8.2)                             | 169 (15.9)                  | 352 (10.2)             |         |
| MDT conference | No 487 (38.6)             | 295 (25.9)                           | 439 (41.3)                  | 1221 (35.2)            | $< 0.001$ |
|                | Yes 764 (60.6)            | 828 (72.6)                           | 570 (53.6)                  | 2162 (62.4)            |         |
|                | Missing 10 (0.8)          | 18 (1.6)                             | 54 (5.1)                    | 82 (2.4)               |         |
| Tumour location |                     |                                       |                             |                        | $< 0.001$ |
| GOJ, Siewert III | 118 (9.4)                | 103 (9.0)                            | 63 (5.9)                    | 284 (8.2)              |         |
| Upper          | 66 (5.2)                  | 52 (4.6)                             | 53 (5.0)                    | 171 (4.9)              |         |
| Middle         | 364 (28.9)                | 362 (31.7)                           | 371 (34.9)                  | 1097 (31.7)            |         |
| Lower          | 421 (33.4)                | 419 (36.7)                           | 419 (39.4)                  | 1259 (36.3)            |         |
| Whole          | 40 (3.2)                  | 36 (3.2)                             | 30 (2.8)                    | 106 (3.1)              |         |
| Missing        | 252 (20.0)                | 169 (14.8)                           | 127 (11.9)                  | 548 (15.8)             |         |
| Resection      | No 773 (61.3)             | 482 (42.2)                           | 276 (26.0)                  | 1531 (44.2)            | $< 0.001$ |
|                | Yes 488 (38.7)            | 659 (57.8)                           | 787 (74.0)                  | 1934 (55.8)            |         |

Values in parentheses are percentages unless indicated otherwise; $^*$ values are mean(s.d.). CCI, Charlson Co-morbidity Index; MDT, multidisciplinary therapy; GOJ, gastro-oesophageal junction. $\chi^2$ test, except. $^\ddagger$ANOVA.
Mean resection rate for each county during the study period
Cut-off for first tertile
Cut-off for second tertile

Fig. 2 Range of resection rates for all counties over the study period
The width of stacked markers represents the number of cases per annual resection rate.

Fig. 3 Kaplan–Meier analysis of overall survival of patients diagnosed with non-metastatic gastric adenocarcinoma in Sweden, 2006–2017, by resection rate tertiles

$P<0.001$ (log rank test).
In this study population of non-metastatic gastric cancers, the overall resection rate was 55.8 per cent. This study found that resection rates also varied greatly between the different counties in Sweden. More advanced tumour stage, greater age, more and severe co-morbidity (higher CCI and ASA grade) were associated with worse survival, as expected. Studies in colorectal and pancreatic cancer have also shown hospital variation in resection rates within a nation. Multiple factors are likely to influence the decision to proceed with surgery, including contiguous organ invasion, extent of lymphatic spread, and response to preoperative chemotherapy, as well as age, co-morbidity, performance status and patients’ wishes. Variations between counties and different years in the resection rate might reflect differences in the quality of investigation and evaluation of these tumour- and patient-related factors; thus, performance of the MDT conference is likely to have a large impact on the treatment recommendation, resulting in differences geographically between counties and time periods.

Stage migration may be a factor influencing survival in favour of the intermediate and high resection rate groups if there were changes in the diagnostic accuracy of cM categorization during the course of the study. The use of PET–CT and diagnostic laparoscopy is likely to increase the accuracy of cM categorization and could bias the results. Data were not included regarding the availability and introduction of these diagnostic tools during the study, and they were not included in the multivariable Cox proportional hazards analysis of overall survival in patients with non-metastatic gastric adenocarcinoma diagnosed in Sweden, 2006–2017.

### Table 2 Cox proportional hazards analysis of overall survival in patients with non-metastatic gastric adenocarcinoma diagnosed in Sweden, 2006–2017

| Resection rate          | Univariable analysis | Multivariable analysis |
|-------------------------|----------------------|------------------------|
|                         | Hazard ratio         | P                      | Hazard ratio         | P                      |
| Low (0–50.0%)           | 1.00 (reference)     | <0.001                 | 1.00 (reference)     | <0.001                 |
| Intermediate (50.1–62.5%)| 0.75 (0.68, 0.83)   | <0.001                 | 0.81 (0.74, 0.89)    | <0.001                 |
| High (62.6–100%)        | 0.74 (0.68, 0.82)   | <0.001                 | 0.80 (0.73, 0.88)    | <0.001                 |
| Age (per year increment) |                      |                        |                      |
| M                       | 1.00 (reference)     | 0.624                  | 1.00 (reference)     | 0.683                  |
| F                       | 0.98 (0.91, 1.06)   | 0.624                  | 1.02 (0.94, 1.10)    | 0.683                  |
| ASA grade               |                      |                        |                      |
| I–II                    | 1.00 (reference)     | <0.001                 | 1.00 (reference)     | –                      |
| III–IV                  | 1.93 (1.78, 2.10)   | <0.001                 | 1.52 (1.39, 1.66)    | <0.001                 |
| Missing                 | 1.20 (1.00, 1.46)   | 0.055                  | 1.12 (0.91, 1.37)    | 0.289                  |
| Clinical tumour stage   |                      |                        |                      |
| I                       | 1.00 (reference)     | <0.001                 | 1.00 (reference)     | <0.001                 |
| II                      | 1.79 (1.59, 2.01)   | <0.001                 | 1.92 (1.71, 2.17)    | <0.001                 |
| III                     | 2.54 (2.24, 2.88)   | <0.001                 | 2.96 (2.60, 3.36)    | <0.001                 |
| IVa                     | 4.50 (2.96, 6.85)   | <0.001                 | 4.95 (3.22, 7.63)    | <0.001                 |
| Missing                 | 2.28 (2.04, 2.56)   | <0.001                 | 1.98 (1.76, 2.22)    | <0.001                 |
| CCI score               |                      |                        |                      |
| 0–1                     | 1.00 (reference)     | 0.821                  | 0.98 (0.87, 1.10)    | 0.709                  |
| 2                       | 1.01 (0.90, 1.14)   | <0.001                 | 1.04 (0.95, 1.14)    | 0.353                  |
| >3                      | 1.21 (1.11, 1.32)   | <0.001                 | 1.04 (0.95, 1.14)    | 0.353                  |
| Educational level (years) |                      |                        |                      |
| <9                      | 1.00 (reference)     | <0.001                 | 1.00 (reference)     | <0.001                 |
| 10–12                   | 0.84 (0.77, 0.92)   | <0.001                 | 0.98 (0.90, 1.08)    | 0.720                  |
| >12                     | 0.71 (0.63, 0.81)   | <0.001                 | 0.96 (0.84, 1.09)    | 0.511                  |
| Missing                 | 1.44 (1.27, 1.63)   | <0.001                 | 1.20 (1.05, 1.37)    | 0.006                  |
| MDT conference          |                      |                        |                      |
| No                      | 1.00 (reference)     | –                      | 1.00 (reference)     | –                      |
| Yes                     | 0.66 (0.61, 0.71)   | <0.001                 | 0.77 (0.71, 0.84)    | <0.001                 |
| Missing                 | 0.66 (0.51, 0.84)   | 0.001                  | 0.90 (0.69, 1.17)    | 0.425                  |

Values in parentheses are 95 per cent confidence intervals. CCI, Charlson Co-morbidity Index; MDT, multidisciplinary therapy.

### Table 3 Sensitivity analysis for Cox proportional hazards model of survival

| Main analysis         | Hazard ratio | P  |
|-----------------------|--------------|----|
| Low                   | 1.00 (reference) |    |
| Intermediate          | 0.81 (0.74, 0.90) | <0.001 |
| High                  | 0.80 (0.73, 0.88) | <0.001 |
| Rate calculated from a 2-year interval mean |                      |    |
| Low                   | 1.00 (reference) |    |
| Intermediate          | 0.88 (0.80, 0.97) | 0.010 |
| High                  | 0.82 (0.74, 0.90) | <0.001 |
| Rate calculated from a 4-year interval mean |                      |    |
| Low                   | 1.00 (reference) |    |
| Intermediate          | 0.95 (0.86, 1.05) | 0.330 |
| High                  | 0.89 (0.81, 0.99) | 0.024 |
| Rate calculated from a 6-year interval mean |                      |    |
| Low                   | 1.00 (reference) |    |
| Intermediate          | 0.91 (0.83, 1.01) | 0.082 |
| High                  | 0.92 (0.83, 1.01) | 0.080 |
| Rate calculated including all patients with metastases or unknown metastatic status |                      |    |
| Low                   | 1.00 (reference) |    |
| Intermediate          | 1.06 (0.99, 1.13) | 0.118 |
| High                  | 0.89 (0.83, 0.96) | 0.001 |
| Rate calculated regarding immortal time bias |                      |    |
| Low                   | 1.00 (reference) |    |
| Intermediate          | 0.82 (0.74, 0.91) | <0.001 |
| High                  | 0.82 (0.73, 0.91) | <0.001 |

Values in parentheses are 95 per cent confidence intervals.
proportional hazards model. Instead, a sensitivity analysis on an extended study population including patients with cM1 and cMx status was carried out, with similar results to those in the main analysis. To investigate any residual baseline differences between the county populations, they were expanded to larger groups by extending the time period from an annual rate to 2-, 4- and 6-year intervals. As seen in Table 3, expanding the time interval modified the results slightly, but the overall interpretation was the same.

A strength of nationwide register studies is the inclusion of the entire population. As all patients, regardless of age or co-morbidity, were included, decision-making processes and outcomes for subgroups of patients that are often excluded from participation in clinical trials can be studied. Inherently, given its observational design, this study has some weaknesses that need to be addressed. As patients were not randomized to different counties, selection bias, as well as residual confounding, could occur. However, for these data, the risk of bias relating to patient or doctor delay, diagnostic capacity and healthcare availability, resulting in more advanced tumour stage and inability to resect owing to inoperable metastatic disease, should be limited, as the study included only potentially curable patients with non-metastatic disease. Additionally, adjustments were made in the regression models for important potentially confounding factors including age, co-morbidity and severity of co-morbidity, although important data such as WHO performance status and tobacco smoking status were not available. To some extent, ASA and CCI grades as variables that describe functional class and co-morbidity might make up for the absence of WHO performance status. Most studies suffer from missing values and, importantly, in the present study some were not evenly distributed between the tertiles. There were fewer missing values for ASA grade and clinical tumour stage among patients with an intermediate or high resection rate compared with the low resection rate tertile. Patients in the high tertile more frequently had missing values for whether a therapy decision was taken in an MDT conference or not, and for educational level.

Chemotherapy as an adjuvant or perioperative treatment to curative surgical resection was not included in this analysis, even though chemotherapy is known to affect survival. There are some data on preoperative chemotherapy in resected patients in though chemotherapy is known to affect survival. There are some data on preoperative chemotherapy in resected patients in

Table 3, expanding the time interval modified the results slightly, but the overall interpretation was the same.

A strength of nationwide register studies is the inclusion of the entire population. As all patients, regardless of age or co-morbidity, were included, decision-making processes and outcomes for subgroups of patients that are often excluded from participation in clinical trials can be studied. Inherently, given its observational design, this study has some weaknesses that need to be addressed. As patients were not randomized to different counties, selection bias, as well as residual confounding, could occur. However, for these data, the risk of bias relating to patient or doctor delay, diagnostic capacity and healthcare availability, resulting in more advanced tumour stage and inability to resect owing to inoperable metastatic disease, should be limited, as the study included only potentially curable patients with non-metastatic disease. Additionally, adjustments were made in the regression models for important potentially confounding factors including age, co-morbidity and severity of co-morbidity, although important data such as WHO performance status and tobacco smoking status were not available. To some extent, ASA and CCI grades as variables that describe functional class and co-morbidity might make up for the absence of WHO performance status. Most studies suffer from missing values and, importantly, in the present study some were not evenly distributed between the tertiles. There were fewer missing values for ASA grade and clinical tumour stage among patients with an intermediate or high resection rate compared with the low resection rate tertile. Patients in the high tertile more frequently had missing values for whether a therapy decision was taken in an MDT conference or not, and for educational level.

Chemotherapy as an adjuvant or perioperative treatment to curative surgical resection was not included in this analysis, even though chemotherapy is known to affect survival. There are some data on preoperative chemotherapy in resected patients in the existing register, but this is presently incomplete.

Geographical variation in the rate of resection for gastric cancer in Sweden appears to result in survival differences between counties. A higher resection rate improved survival for the entire population of potentially curable, non-metastatic gastric cancer. There still seems to be room for improvement in standardizing MDT decision-making in order to offer as many patients as possible a curative resection of gastric cancer.

### Funding
Swedish Cancer Society M.L.; CAN 2018/837 and J.H.; CAN 2017/1086.

### Acknowledgements
This study was funded by a research grant from the Swedish Cancer Society. M.L. and J.H. are currently supported by a grant from the Swedish Cancer Society, an independent non-profit organization that had no impact on the study design, data analysis or manuscript writing.

### Disclosure
The authors declare no conflict of interest.

### References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424
2. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948–1957
3. Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:616–628
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20
5. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011;11:329
6. Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T; Southwest Oncology Group and the Gastric Intergroup. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002;9:278–286
7. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastro-oesophageal junction. N Engl J Med 2001;345:725–730
8. Noh SH, Park SR, Yang HK, Chung HC, Chung J, Kim SW et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1369–1376
9. Park SH, Sohn TS, Lee J, Lim do H, Hong ME, Kim KM et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol 2015;33:3130–3136
10. Sakuramoto S, Sasaki M, Yamaguchi T, Kinoshita T, Fuji M, Nashimoto A et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810–1820
11. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715–1721
12. Akoh JA, Macintyre IM. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 1992;79:293–299
13. van Putten M, Verhoeven RH, van Sandick JW, Plukker JT, Lemmens VE, Wijnhoven BP et al. Hospital of diagnosis and probability of having surgical treatment for resectable gastric cancer. Br J Surg 2016;103:233–241
14. Linder G, Lindblad M, Djerf P, Elbe P, Johansson J, Lundell L et al. Validation of data quality in the Swedish National Register for oesophageal and gastric cancer. Br J Surg 2016;103:1326–1335

15. Kung CH, Song H, Ye W, Nilsson M, Johansson J, Rouvelas I et al. Extent of lymphadenectomy has no impact on postoperative complications after gastric cancer surgery in Sweden. Chin J Cancer Res 2017;29:313–322

16. Kung CH, Tsai JA, Lundell L, Johansson J, Nilsson M, Lindblad M. Nationwide study of the impact of D2 lymphadenectomy on survival after gastric cancer surgery. BJS Open 2020;4:424–431

17. Dikken JL, van Sandick JW, Allum WH, Johansson J, Jensen LS, Putter H et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg 2013;100:83–94

18. Giesen LJX, van Erning FN, Vissers PAJ, Maas H, Rutten HJT, Lemmens V et al. Inter-hospital variation in resection rates of colon cancer in the Netherlands: a nationwide study. Eur J Surg Oncol 2019;45:1882–1886

19. Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut 2019;68:130–139